Remove the SIM card from its packaging and place it on the tray. The kit has nano, micro, and standard sizes. Insert the SIM ...

Last year, one security device we saw emerge as an important piece to a smart home was the pan and tilt security camera. We ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

Consumer spending will play a large role in the economy in 2025, as it always does. However, the impact has often been overstated. Nonetheless, the strong footing of households—in the aggregate ...

The world's biggest gathering of humans is also a much-awaited event for India's consumer businesses. In fact, the Kumbh is the most visible part of a big driver of India's economy, the festival cycle ...

(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...

Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising ... as J&J seeks to bolster its portfolio following the spin-off of its consumer health division ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...